Ratings by Daiwa Securities (Narumi Nakagiri)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/21/2023 | Amgen | AMGN | Upgrade | Buy (1) (Neutral (3)) |
278.44 (273.01) |
-1.95% | Details | |
| 11/2/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (3) (Outperform (2)) |
51.53 (48.86) |
-5.18% | Details | |
| 2/14/2023 | Merck | MRK | Maintain | Outperform (2) (N/A) |
|
Details | ||
| 8/12/2022 | Amgen | AMGN | Maintain | Buy (1) (N/A) |
|
Details | ||
| 7/6/2022 | Merck | MRK | Upgrade | Outperform (2) (Sell (5)) |
92.64 (127.00) |
37.09% | Details | |
| 5/6/2022 | Abbvie | ABBV | Downgrade | Sell (5) (Buy (1)) |
151.59 (167.80) |
10.69% | Details | |
| 12/16/2021 | Merck | MRK | New Coverage | Neutral (3) (N/A) |
73.72 (127.00) |
72.27% | Details | |
| 9/23/2021 | Amgen | AMGN | Downgrade | Neutral (3) (Outperform (2)) |
213.64 (273.01) |
27.79% | Details | |
| 8/5/2021 | Amgen | AMGN | Downgrade | Outperform (2) (Buy (1)) |
228.31 (273.01) |
19.58% | Details |
